Previous 10 | Next 10 |
2023-09-13 10:00:00 ET Finding dividend stocks worth holding onto for good isn't an easy task. Investors shouldn't necessarily rely on a company's current dividend yield to make that decision. Recent history has shown that a high yield is only as secure as the business that supports it. M...
2023-09-11 12:04:11 ET More on Novartis Seeking Alpha’s Quant Rating on Novartis Historical earnings data for Novartis Dividend scorecard for Novartis Financial information for Novartis Novartis: Q2 Beats Expectations, But Still Pricey ...
2023-09-11 11:49:04 ET Summary Bayer's stock has had a volatile performance, reaching highs and lows since December 2022, when I first wrote about this company. Both from a relative and intrinsic standpoint, Bayer seems to be severely undervalued. Bayer has both short-ter...
Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization PR Newswire Company Contact: Novartis Pharmaceuticals Corporation 1-888-669-6682 EAST HANOVER, N.J. , ...
2023-09-11 08:49:41 ET More on Bausch + Lomb Seeking Alpha’s Quant Rating on Bausch + Lomb Historical earnings data for Bausch + Lomb Financial information for Bausch + Lomb Bausch + Lomb: Growth Should Accelerate As Supply Issues Ease Bausch +...
2023-09-11 08:20:32 ET More on Marker Financial information for Marker Therapeutics For further details see: Marker gains as lymphoma therapy leads to complete remission
2023-09-10 05:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-09-09 08:26:31 ET Summary Alnylam has an upcoming FDA advisory committee meeting on the company's application for Onpattro in ATTR-CM, and I see some risk of a negative committee vote. Onpattro has met or exceeded the efficacy targets established with the FDA, but I expect th...
2023-09-08 15:00:57 ET More on the markets The Unemployment Rate Just Signaled That A Recession May Occur Within The Next 6 Months High Yield Signal Does Not Align With Bearish Outlook For SPY SPY: The Calm Before The Storm Bulls vs. Bears: SA analysts weigh ...
2023-09-06 10:21:15 ET More on AbbVie, Novartis, etc. AbbVie: Proving The Bears Wrong Again As Shares Surged AbbVie Unleashed: 4% Yield, Potentially 40% Undervalued AbbVie: Balance Is Everything AbbVie: Still A Buy According To Buffett's 10xEBT Rule A...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...